Evenity (Romosozumab) Autoimmune Disease Considerations

What Is Romosozumab and Why Does It Matter for Autoimmune Patients?

Romosozumab is a humanized monoclonal IgG2 antibody that binds and inhibits sclerostin, a glycoprotein encoded by the SOST gene that ordinarily suppresses Wnt/beta-catenin signaling in osteoblasts. Blocking sclerostin simultaneously increases bone formation and decreases bone resorption, a mechanism no prior osteoporosis drug achieves. The FDA approved romosozumab in April 2019 under the brand name Evenity for postmenopausal women with osteoporosis at high or very high fracture risk, defined as a prior osteoporotic fracture, a T-score at or below -2.5, or multiple clinical risk factors. 1

Autoimmune diseases create a disproportionate osteoporosis burden. Chronic glucocorticoid use, systemic inflammation, and disease-related immobility all accelerate bone loss. Patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and ankylosing spondylitis therefore represent a large fraction of the severe-osteoporosis population most likely to be considered for romosozumab. 2

The Sclerostin-Immunity Connection

Sclerostin is not expressed exclusively in bone. Research has detected SOST mRNA in CD4+ and CD8+ T cells and in synovial tissue from RA patients. 3 Wnt signaling modulates T-cell activation, regulatory T-cell differentiation, and dendritic cell function. Inhibiting sclerostin could therefore alter immune cell behavior, though clinical data in autoimmune populations remain sparse.

A 2022 translational study published in Annals of the Rheumatic Diseases found that sclerostin blockade in murine collagen-induced arthritis reduced osteoclast activity and synovial inflammation scores, suggesting a potential anti-inflammatory co-benefit in inflammatory arthritis. 4 Those findings have not been replicated in human RCTs.

Glucocorticoid-Induced Osteoporosis Context

The American College of Rheumatology 2022 guidelines on glucocorticoid-induced osteoporosis (GIOP) list romosozumab as a conditional recommendation for patients at very high fracture risk who are on long-term glucocorticoid therapy and have already failed or cannot tolerate bisphosphonates. 5 Conditional means the guideline panel judged benefits likely outweigh harms for most patients but acknowledged limited evidence. Prescribers should document that judgment explicitly in the chart.

The ARCH Trial: Key Efficacy and Safety Data

The key ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and a prior vertebral fracture to romosozumab 210 mg SC monthly for 12 months followed by alendronate, versus alendronate alone for 24 months total. 6

Fracture Outcomes

At 24 months, the romosozumab-then-alendronate sequence reduced new vertebral fractures by 48% relative to alendronate alone (6.2% vs. 11.9%; P<0.001). 6 Clinical fractures fell by 27% (9.7% vs. 13.0%; P<0.001). Hip fracture rates were numerically lower in the romosozumab arm (2.0% vs. 3.2%) but that difference did not reach statistical significance in the overall ARCH population.

The earlier FRAME trial (N=7,180) compared romosozumab with placebo for 12 months, then both groups transitioned to denosumab for 12 more months. 7 New vertebral fractures at 12 months were reduced by 73% (0.5% vs. 1.8%; P<0.001). Nonvertebral fracture reduction was significant only in a pre-specified subgroup excluding Latin America.

The Cardiovascular Signal

ARCH enrolled patients with higher baseline cardiovascular risk than FRAME. Serious cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group, an imbalance that drove the FDA's 2019 boxed warning. 6 FRAME, conducted in a lower-CV-risk population, did not show a statistically significant CV difference.

The mechanistic hypothesis involves sclerostin's role in vascular calcification. Sclerostin may protect arterial walls from excessive mineralization; inhibiting it could accelerate vascular calcium deposition. A Mendelian randomization study using SOST genetic variants found suggestive associations between lower sclerostin levels and higher coronary artery disease risk (OR 1.14 per SD decrease; P=0.03). 8 That finding supports biological plausibility rather than proving causation.

Autoimmune Disease-Specific Considerations

No randomized controlled trial has enrolled an exclusively autoimmune patient population for romosozumab. Clinicians must therefore extrapolate from mechanistic data, post-hoc subgroup analyses, and case series.

Rheumatoid Arthritis

RA patients on methotrexate, hydroxychloroquine, or JAK inhibitors represent the most common autoimmune subgroup considered for romosozumab. Methotrexate does not appear to interfere with romosozumab pharmacokinetics; both drugs are given by subcutaneous or intramuscular injection on separate schedules, and no pharmacokinetic interaction studies have been published. 9

Tocilizumab (IL-6 receptor blockade) is worth specific attention. IL-6 promotes osteoclastogenesis. Patients already on tocilizumab for RA may have partially suppressed bone resorption at baseline, potentially altering the antiresorptive component of romosozumab's dual mechanism. No head-to-head data exist. Clinicians should obtain baseline bone turnover markers (P1NP for formation, serum CTX for resorption) before starting romosozumab in this subset to track response.

Cardiovascular risk in RA is independently elevated, with a relative risk of major adverse cardiovascular events approximately 1.5 times that of the general population. 10 Stacking romosozumab's modest CV signal on top of pre-existing RA-related CV risk warrants a cardiology or primary care co-sign before prescribing.

Systemic Lupus Erythematosus

SLE patients, especially those on chronic hydroxychloroquine and periodic pulse-dose corticosteroids, frequently develop severe osteoporosis by their fourth or fifth decade. Hydroxychloroquine has no known pharmacokinetic interaction with romosozumab. 11

Anti-phospholipid antibody syndrome (APS), present in roughly 30-40% of SLE patients, substantially increases thromboembolic and cardiovascular risk. The FDA label advises against starting romosozumab in patients with a myocardial infarction or stroke within the preceding 12 months. 1 For an SLE patient with APS and a recent cardiovascular event, the risk-benefit calculation likely favors either teriparatide or continued bisphosphonate therapy over romosozumab.

Inflammatory Bowel Disease

IBD-associated osteoporosis is driven by malabsorption, corticosteroid exposure, and elevated tumor necrosis factor (TNF). Calcium and vitamin D absorption may be compromised, and the FDA label requires that hypocalcemia be corrected before the first romosozumab dose. 1 Clinicians managing Crohn's disease or ulcerative colitis patients should check 25-hydroxyvitamin D, serum calcium, and albumin before prescribing.

Vedolizumab and ustekinumab, common biologics in IBD, are gut-selective or IL-12/23-targeted agents with no identified pharmacodynamic overlap with sclerostin inhibition. Drug-drug interaction data are absent from the literature, but mechanistic conflict is unlikely.

Ankylosing Spondylitis and Other Spondyloarthropathies

Ankylosing spondylitis (AS) presents a paradox. Patients with AS often have low bone density at the femoral neck despite syndesmophyte formation in the spine, and sclerostin is paradoxically elevated in AS serum. 12 Some researchers hypothesized that sclerostin inhibition could worsen syndesmophyte progression. A 2021 systematic review found no convincing clinical evidence that romosozumab accelerates heterotopic ossification in AS patients, but human trial data remain absent. 13

Immunogenicity in Immunosuppressed Patients

Approximately 18% of romosozumab-treated patients in FRAME and ARCH developed anti-drug antibodies (ADA). Neutralizing antibodies appeared in fewer than 1% of subjects. 7 The clinical significance of non-neutralizing ADA for bone turnover markers or fracture outcomes was not demonstrated in either trial.

How Immunosuppression Changes the Picture

Patients on disease-modifying antirheumatic drugs (DMARDs) or biologics present a theoretically altered immunogenicity profile. Methotrexate reduces ADA formation against biologics like adalimumab by about 30-50% in RA trials. 14 Whether the same applies to romosozumab has not been formally studied.

A practical three-step framework for managing romosozumab immunogenicity in autoimmune patients:

1. Baseline ADA testing is not routinely indicated before starting romosozumab; no pre-treatment ADA screen is recommended in the FDA label.
2. Monitor bone turnover markers at 3 months. A rise in P1NP of at least 25 mcg/L from baseline suggests adequate anabolic response. A blunted response warrants consideration of ADA testing.
3. Do not extend the 12-month course. Efficacy beyond 12 monthly injections has not been established, and an extended course does not appear to overcome potential immunogenicity.

Injection-Site Reactions

In FRAME, injection-site reactions occurred in 5.1% of romosozumab patients versus 2.9% in placebo. 7 Patients already injecting biologics (e.g., adalimumab, etanercept, secukinumab) are accustomed to rotating sites. Alternating the romosozumab injection to the abdomen when the thigh is occupied by a biologic on the same day reduces local tissue load.

Cardiovascular Risk Assessment Before Prescribing

The FDA label carries a boxed warning stating that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death." 1 A pre-treatment cardiovascular assessment should include:

• Review of prior MI, stroke, or transient ischemic attack within 12 months (absolute contraindication per label)
• Current statin use and LDL target achievement
• Blood pressure at the visit
• 10-year ASCVD risk calculation using the AHA/ACC pooled cohort equation 15

Autoimmune diseases like RA and SLE independently worsen the ASCVD risk score. Clinicians who calculate a 10-year ASCVD risk above 20% in an autoimmune patient scheduled for romosozumab should document a shared decision-making conversation and consider a cardiology consultation.

The European Society of Cardiology's position paper on cancer therapy-related cardiovascular toxicity includes a note that sclerostin inhibitors warrant CV monitoring analogous to that applied to other anabolic bone agents, though romosozumab is not a cancer drug. 16

Hypocalcemia Risk: Heightened in Autoimmune Populations

Hypocalcemia is listed as a contraindication in the romosozumab label. 1 The anabolic spike in bone formation rapidly mineralizes new osteoid, drawing calcium from the extracellular compartment. This effect peaks in the first 4 weeks after each injection.

Who Is at Greater Risk?

Autoimmune patients carry several hypocalcemia risk amplifiers:

• Chronic glucocorticoid use impairs intestinal calcium absorption and increases renal calcium loss. 17
• IBD-related malabsorption reduces dietary calcium and vitamin D uptake.
• Hypoparathyroidism from autoimmune thyroid disease or prior thyroid surgery blunts the PTH-mediated calcium-rescue response.

Pre-treatment labs should include serum calcium, albumin (to calculate corrected calcium), phosphorus, 25-OH vitamin D, and PTH. Correct 25-OH vitamin D to at least 30 ng/mL and ensure daily calcium intake of 1,000-1,200 mg before the first dose. 18

Sequencing Romosozumab With Other Osteoporosis and Autoimmune Therapies

After Denosumab

The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines note that transitioning from denosumab to romosozumab is not well-studied and carries a theoretical risk of rebound bone loss if denosumab is stopped abruptly. 19 The preferred sequence is romosozumab first, then antiresorptive therapy (alendronate or denosumab), not the reverse.

After Teriparatide

Teriparatide (PTH 1-34) is the most common prior anabolic agent encountered when romosozumab is considered. A 12-month course of teriparatide followed by romosozumab produced additive gains in lumbar spine BMD in a small open-label study (N=12), but this sequence is not FDA-approved and data are preliminary. 20

Concurrent Bisphosphonates

Adding a bisphosphonate during the 12-month romosozumab course blunts the anabolic effect by suppressing osteoblast activity downstream of Wnt signaling. The FDA label and both key trials support sequential, not concurrent, use. After the 12-month romosozumab course ends, alendronate or zoledronic acid consolidates the BMD gains.

Practical Prescribing Checklist for Autoimmune Patients

Before writing the first romosozumab prescription for a patient with a concurrent autoimmune condition, the following steps reduce avoidable harm:

1. Confirm no MI or stroke within 12 months.
2. Calculate corrected serum calcium and correct any deficit.
3. Check 25-OH vitamin D and supplement to 30 ng/mL minimum.
4. Calculate 10-year ASCVD risk; document the shared decision-making conversation if risk exceeds 20%.
5. Identify all concurrent biologics and DMARDs; document that no pharmacokinetic interaction data exist.
6. Order baseline P1NP and serum CTX to track anabolic and antiresorptive response.
7. Schedule a 3-month follow-up visit to reassess bone turnover markers and screen for hypocalcemia symptoms.
8. Plan the post-romosozumab antiresorptive agent before the 12-month course ends to prevent BMD loss reversal. 19

Monitoring Parameters During the 12-Month Course

Serum calcium should be checked at 4 weeks after the first injection and after any dose change. 1 P1NP typically peaks around months 1-3 and then falls toward baseline by month 12 as the anabolic window closes. A P1NP that fails to rise above 25 mcg/L at 3 months may indicate inadequate response, possible ADA interference, or poor adherence.

Patients on TNF inhibitors or IL-6 inhibitors for their autoimmune condition should have their C-reactive protein (CRP) monitored as usual. Romosozumab does not independently raise inflammatory markers, and a rising CRP in this context should prompt evaluation of autoimmune disease flare rather than attribution to the bone agent.

Renal function matters. Romosozumab is not renally cleared as an intact antibody, but calcium and phosphorus homeostasis are impaired in chronic kidney disease (CKD). The ARCH and FRAME trials excluded patients with estimated GFR below 30 mL/min/1.73 m2. Autoimmune nephritis in SLE or IgA nephropathy in IBD-associated conditions may place patients near or below that threshold. 6